INNATE PHARMA Aktie [WKN DE: A0LCUJ / ISIN: FR0010331421]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu INNATE PHARMA SA

05.10.23		Innate Pharma Provides Update on Lacutamab Clinical Program (Businesswire)
14.09.23		Innate Pharma Reports First Half 2023 Financial Results and Business Update (Businesswire)
29.08.23		Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update (Businesswire)
10.08.23		Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
11.07.23		First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma (Businesswire)
07.07.23		Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 (Businesswire)
26.06.23		First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer (Businesswire)
16.06.23		Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria (Businesswire)
12.06.23		Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma (Businesswire)
10.06.23		Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress (Businesswire)
08.06.23		SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies (Businesswire)
07.06.23		Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 (Businesswire)
26.05.23		Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML (Businesswire)
23.05.23		Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
15.05.23		Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress (Businesswire)
12.05.23		Outcome of Innate Pharma’s 2023 Annual General Meeting (Businesswire)
10.05.23		Innate Pharma Reports First Quarter 2023 Financial Results and Business Update (Businesswire)
09.05.23		Number of shares and voting rights of Innate Pharma as of May 1, 2023 (Businesswire)
03.05.23		Innate Pharma Announces Conference Call and Webcast for Q1 Business Update (Businesswire)
03.05.23		Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting (Businesswire)
26.04.23		Innate Pharma Establishes a New At-The-Market ("ATM”) Program on Nasdaq (Businesswire)
21.04.23		Innate Pharma to Participate in Upcoming Investor Conference (Businesswire)
18.04.23		Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023 (Businesswire)
07.04.23		Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023 (Businesswire)
06.04.23		Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F (Businesswire)
03.04.23		Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program (Businesswire)
23.03.23		Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update (Businesswire)
20.03.23		Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023 (Businesswire)
16.03.23		Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results (Businesswire)
13.03.23		Innate Pharma Provides Update on Silicon Valley Bank Exposure (Businesswire)
21.02.23		Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023 (Businesswire)
07.02.23		Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
25.01.23		Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers (Businesswire)
16.01.23		Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology (Businesswire)
19.12.22		Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology (Businesswire)
10.12.22		Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022 (Businesswire)
09.12.22		Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022 (Businesswire)
01.12.22		Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 (Businesswire)
14.11.22		Innate Pharma Reports Third Quarter Financial Results (Businesswire)
07.11.22		Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update (Businesswire)
04.11.22		Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022 (Businesswire)
02.11.22		Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
20.10.22		Innate Pharma 2023 Financial Calendar (Businesswire)
23.09.22		Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides (Businesswire)
15.09.22		Innate Pharma Reports First Half 2022 Financial Results and Business Update (Businesswire)
08.09.22		Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update (Businesswire)
05.09.22		Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022 (Businesswire)
23.08.22		Innate Pharma to Participate in Upcoming Investor Conferences (Businesswire)
08.08.22		Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022 (Businesswire)
01.08.22		Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 20:11
Kaufwert:	EUR
	Hinzufügen Speichern